Navigation Links
WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
Date:6/10/2008

SHANGHAI, China, June 10 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it has signed a new three-year collaboration agreement with AstraZeneca.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

In April 2006, WuXi PharmaTech and AstraZeneca entered into a two-year US$14 million collaboration agreement that WuXi PharmaTech successfully delivered more than 100,000 compounds two months ahead of schedule.

"This new collaboration agreement further strengthens our already productive relationship with AstraZeneca, and it is the direct result of our research capability and firm commitment to quality and customer satisfaction," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, "We are hopeful that with our strong and growing drug R&D capabilities the expansion of our collaboration will help AstraZeneca achieve its strategic goals."

Under the new collaboration agreement WuXi PharmaTech will synthesize compounds, according to AstraZeneca's designs, which will further expand AstraZeneca's global compound collection.

"The collaboration with WuXi PharmaTech has exceeded our expectations delivering value to AstraZeneca beyond the cost savings in labor and materials," said Deborah Hartman, Vice President, Lead Generation Discovery Enabling Capabilities and Sciences (DECS), AstraZeneca, "We are looking forward to the prospect of building on this success through our expanded relationship."

High Throughput Screening remains a major source of chemical starting points, making it important to generate many high quality compounds with the proper purity and targeted characteristics. WuXi PharmaTech has developed an innovative, scalable and hi
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
2. WuXi PharmaTech Announces First Quarter 2008 Results
3. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
4. WuXi PharmaTech Schedules First Quarter 2008 Earnings Release on Tuesday, May 27, 2008
5. WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
6. Quest PharmaTech Receives Support from National Research Councils Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer
7. WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering
8. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
9. WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008
10. WuXi PharmaTech Completes Acquisition of AppTec
11. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... HONG KONG , June 2, 2015 /PRNewswire/ -- China Cord ... "us" and "our"), China,s leading provider ... and stem cell storage services, today announced that the Special ... has appointed Houlihan Lokey ( China ... Steen & Hamilton LLP as its United ...
(Date:6/2/2015)... German-based Moenninghoff has designated the R.M. Hoffman Company ... Moenninghoff product line . , Moenninghoff President ... the R.M. Hoffman Company will be representing Moenninghoff in ... this is a strategically important step. We are ... distributor we need to successfully grow our business in ...
(Date:6/1/2015)... YONGIN, South Korea , June 1, ... Green Cross Biotherapeutics Inc. (GCBT) kicked off construction today ... the Montreal Technoparc,s Saint-Laurent Campus. The CA$315 million project ... in Canada in the biopharmaceutical ... intravenous immunoglobulin (IVIG) and albumin manufacturing plant in ...
(Date:6/1/2015)... 1, 2015  Novartis is highlighting data from ... an investigational chimeric antigen receptor (CAR) T cell ... of specific types of hard-to-treat non-Hodgkin lymphoma. Findings ... of Pennsylvania,s Perelman School of Medicine (Penn) in ... B-cell lymphoma (DLBCL) and follicular lymphoma (FL) found ...
Breaking Biology Technology:China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 2China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 3R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6
... Europe Ongoing , , DALLAS, June 10 ... (OTC Bulletin Board: ACCP) , announced ... States Patent and Trademark Office that two US patents relating to ... for the management of mucositis will issue in June as US ...
... Calif., June 10 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Business Officer of BioMarin, will present a company update at the ... 2009 at 8:30 a.m. ET. , , Interested ... via the investor section of the BioMarin website, www.BMRN.com ...
... 10 Delcath Systems, Inc. (Nasdaq: DCTH ), ... (PHP(TM)) System for the treatment of cancers of the liver, ... to sell 869,565 units, each unit consisting of one of ... common shares, for gross proceeds of approximately $3 million, before ...
Cached Biology Technology:Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM) 2Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM) 3BioMarin to Present at the Jefferies Healthcare Conference 2Delcath Enters Agreement to Sell 869,565 Units 2Delcath Enters Agreement to Sell 869,565 Units 3
(Date:5/26/2015)... 26, 2015 Research and ... of the "Saudi Arabia Biometric Systems Market ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems ... is projected to grow at over 22% CAGR ... attributed to the surging demand for better biometric ...
(Date:5/22/2015)... DALLAS , May 22, 2015 ... Recognition Market by Solution (2D, 3D, Thermal, Emotion, Forensic), by ... End User (Government and Utilities, Consumer and Home) - ... Market to grow from $2.77 Billion in 2015 to ... Browse 79 market data Tables and ...
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
... identifies regions of the human genome that regulate gene expression ... number of human diseases, according to researchers at Dukes Institute ... DNA in our bodies is packaged, or tightly structured, said ... of the senior investigators on this study. Our goal was ...
... sliding against joints, ink jets splashing on paperliving ... However important these liquid/solid boundaries may be, conventional ... interfaces in their natural environments. Now, researchers at ... and the University of Minnesota have demonstrated a ...
... According to a study published in Nature by researchers ... the hydrology and chemistry of the Mississippi River, injecting ... discharge during the past 50 years. LSU Professor ... with their colleagues at Yale, tracked changes in the ...
Cached Biology News:Search for the 'on' switches may reveal genetic role in development and disease 2Videos extract mechanical properties of liquid-gel interfaces 2LSU, Yale team study agricultural impact on Mississippi River 2
... pressure gradient system uses three Adept CE ... a flow rate in one microlitre increaments. ... added flexibility. System control and data processing ... interface unit, CE 4900., Column heater/chillers can be ...
... The Adept HPLC range has ... Q-Adept systems, a quaternary low ... binary low pressure mixing pump. ... compact systems add even more ...
capacity 250 mL...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z35,347-7) ...
Biology Products: